Skip to content

Author

Yu-Tao Xia

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice

Claudin 18.2 (CLDN18.2) has rapidly become a major target in solid-tumor oncology. Zolbetuximab, the first anti-CLDN18.2 antibody, was approved in 2024 for HER2-negative, CLDN18.2-high advanced gastric and gastro-esophageal junction adenocarcinoma, and more than one hundred CLDN18.2-directed trials are now under way ac...

Yu-Tao Xia, Ming-Fang Wang, Tao-Sheng Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.